RBC Capital analyst Michael J. Yee commented on Esperion Therapeutics (NASDAQ: ESPR) after it provided an update on ETC-1002 development ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE